Suppr超能文献

美国各州对大麻产品标签的要求。

Requirements for Cannabis Product Labeling by U.S. State.

机构信息

Population Studies Center, Institute for Social Research, University of Michigan, Ann Arbor, Michigan, USA.

Department of Community Health and Health Behavior, School of Public Health and Health Professions, University at Buffalo, SUNY, Buffalo, New York, USA.

出版信息

Cannabis Cannabinoid Res. 2022 Apr;7(2):156-160. doi: 10.1089/can.2020.0079. Epub 2021 Jan 11.

Abstract

As more states allow for medical and nonregistered adult cannabis (i.e., marijuana) use, ensuring proper utilization should be a priority. Standardized labeling for foods and pharmaceutical drugs promotes consumer safety. This study investigated cannabis product labeling requirements in the United States. Researchers compiled the requirements for cannabis product labeling across 31 U.S. states with medical cannabis programs from state regulatory publications. Information requirements ranged considerably by U.S. state. All states required delta-9-tetrahydrocannabinol content and manufacturer contact information, >80% of states required the batch number, health risks, production tracking, a cannabis symbol, cannabidiol content, children disclaimer, and an impairment disclaimer. There appeared to be a random pattern in requirements for other specific items. The relationships between the extent of cannabis product labeling requirements and the number of years that a state had a medical cannabis program or whether states allowed nonregistered adult use cannabis were not significant, although there was a trend for nonregistered adult use states to require more recommended label attributes. A comprehensive framework for cannabis use is needed to protect the public, maximize benefits, and minimize harms and risks. Standardization of cannabis product labeling requirements would benefit consumers and promote safer and more effective usage of cannabis products.

摘要

随着越来越多的州允许医疗和非注册成人使用大麻(即大麻),确保合理使用大麻应成为当务之急。食品和药品的标准化标签可促进消费者安全。本研究调查了美国的大麻产品标签要求。

研究人员从有医疗大麻项目的 31 个美国州的州监管出版物中整理了大麻产品标签的要求。信息要求因美国各州而异。所有州都要求标明四氢大麻酚含量和制造商联系信息,超过 80%的州要求标明批次号、健康风险、生产跟踪、大麻符号、大麻二酚含量、儿童警告和损伤警告。对于其他特定项目的要求似乎存在随机模式。大麻产品标签要求的程度与一个州拥有医疗大麻项目的年限之间,以及各州是否允许非注册成人使用大麻之间没有显著关系,尽管有趋势表明允许非注册成人使用大麻的州要求更多推荐的标签属性。

需要建立一个全面的大麻使用框架,以保护公众,最大程度地发挥其益处,并将危害和风险降到最低。大麻产品标签要求的标准化将使消费者受益,并促进大麻产品更安全、更有效的使用。

相似文献

1
Requirements for Cannabis Product Labeling by U.S. State.美国各州对大麻产品标签的要求。
Cannabis Cannabinoid Res. 2022 Apr;7(2):156-160. doi: 10.1089/can.2020.0079. Epub 2021 Jan 11.
4
A Clinical Framework for Evaluating Cannabis Product Quality and Safety.评估大麻产品质量和安全的临床框架。
Cannabis Cannabinoid Res. 2023 Jun;8(3):567-574. doi: 10.1089/can.2021.0137. Epub 2022 Jan 18.
6
U.S. State approaches to cannabis licensing.美国各州的大麻许可发放方式。
Int J Drug Policy. 2022 Aug;106:103755. doi: 10.1016/j.drugpo.2022.103755. Epub 2022 Jun 9.

引用本文的文献

5
Evaluations of State Medical Cannabis Programs in the USA: A Narrative Review.美国各州医用大麻项目评估:一项叙述性综述
Med Cannabis Cannabinoids. 2024 Nov 6;7(1):243-256. doi: 10.1159/000542472. eCollection 2024 Jan-Dec.
10

本文引用的文献

1
Labeling of Cannabidiol Products: A Public Health Perspective.大麻二酚产品的标签:公共卫生视角
Cannabis Cannabinoid Res. 2020 Dec 15;5(4):274-278. doi: 10.1089/can.2019.0101. eCollection 2020.
5
Cannabis labelling and consumer understanding of THC levels and serving sizes.大麻标签和消费者对 THC 水平和份量的理解。
Drug Alcohol Depend. 2020 Mar 1;208:107843. doi: 10.1016/j.drugalcdep.2020.107843. Epub 2020 Feb 7.
7
Medical Use of Cannabis in 2019.2019年大麻的医疗用途。
JAMA. 2019 Sep 10;322(10):974-975. doi: 10.1001/jama.2019.11868.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验